Becton, Dickinson and Company (BDX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Becton, Dickinson and Company (BDX) Healthcare & Pipeline Overview

Becton, Dickinson and Company (BDX) is a leading medical technology company providing essential medical supplies, devices, and diagnostic systems across healthcare settings globally. With a diverse portfolio spanning medical, life sciences, and interventional segments, BDX maintains a strong market presence through innovation and established distribution networks, facing competition from major healthcare corporations.

What Is the Investment Thesis for BDX?

Becton, Dickinson and Company presents a compelling investment case due to its diversified product portfolio, global reach, and consistent revenue generation. With a market capitalization of $51.7B and a dividend yield of 2.50%, BDX offers a blend of stability and income. The company's P/E ratio of 36.4 reflects investor confidence in its earnings potential. Key growth catalysts include expanding its presence in emerging markets and introducing innovative medical technologies. However, potential risks include increasing competition and regulatory challenges. The company's beta of 0.35 indicates lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

BDX Key Highlights

Market Cap of $51.7B demonstrates significant investor confidence and scale within the medical technology industry.

• P/E Ratio of 36.4 indicates a premium valuation, reflecting expectations of future earnings growth.
• Profit Margin of 5.3% highlights the company's ability to generate earnings from its revenue streams.
• Gross Margin of 46.5% showcases efficient cost management in the production and distribution of medical supplies and devices.
• Dividend Yield of 2.50% provides a steady income stream for investors, enhancing the stock's attractiveness.

Who Are BDX's Competitors?

BDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BDX's Key Strengths?

Diversified product portfolio across medical, life sciences, and interventional segments.

• Global presence with established distribution networks.
• Strong brand reputation and customer loyalty.
• Consistent revenue generation and profitability.

What Are BDX's Weaknesses?

Exposure to regulatory risks and compliance requirements.

• Dependence on healthcare spending and reimbursement policies.
• Potential for product recalls and liability claims.
• Competition from other medical technology companies.

What Could Drive BDX Stock Higher?

Launch of new diagnostic platforms for rapid disease detection in Q3 2026.

• Expansion of digital healthcare solutions to improve patient outcomes and reduce healthcare costs.
• Strategic partnerships with healthcare providers to enhance market access and customer engagement.

What Are the Key Risks for BDX?

Rich valuation — a P/E of 36.4 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Increased competition from established and emerging medical technology companies.
• Changes in healthcare regulations and reimbursement policies.
• Product recalls and liability claims related to medical devices.
• Economic downturns and reduced healthcare spending.

What Are the Growth Opportunities for BDX?

• Expansion in Emerging Markets: Becton, Dickinson and Company has a significant opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. These markets offer substantial growth potential for BDX's medical supplies, devices, and diagnostic products. By establishing strategic partnerships and tailoring its product offerings to meet local needs, BDX can capitalize on the growing demand for healthcare solutions in these regions. This expansion could contribute to a 10-15% increase in revenue over the next five years.
• Development of Innovative Medical Technologies: Investing in research and development to create innovative medical technologies is crucial for Becton, Dickinson and Company to maintain its competitive edge. The company can focus on developing advanced diagnostic tools, minimally invasive surgical devices, and personalized medicine solutions. By securing patents and regulatory approvals for these new technologies, BDX can capture a larger share of the market and drive revenue growth. The market for innovative medical technologies is projected to reach $200 billion by 2028.
• Strategic Acquisitions and Partnerships: Becton, Dickinson and Company can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. By acquiring companies with complementary technologies or established distribution networks, BDX can accelerate its growth and enhance its market position. These acquisitions can provide access to new markets, innovative products, and skilled talent. The company should focus on acquiring companies that align with its strategic objectives and offer synergies in terms of operations and technology.
• Enhancing Digital Healthcare Solutions: The increasing adoption of digital healthcare technologies presents a significant growth opportunity for Becton, Dickinson and Company. The company can develop and offer digital solutions such as remote patient monitoring systems, telehealth platforms, and data analytics tools. These solutions can improve patient outcomes, reduce healthcare costs, and enhance the efficiency of healthcare delivery. The market for digital healthcare solutions is projected to reach $300 billion by 2027.
• Focus on Personalized Medicine: Personalized medicine, which tailors medical treatment to individual patient characteristics, is a rapidly growing field. Becton, Dickinson and Company can capitalize on this trend by developing diagnostic tools and therapies that enable personalized treatment decisions. This includes developing advanced molecular diagnostics, genetic testing services, and targeted drug delivery systems. By offering personalized medicine solutions, BDX can improve patient outcomes and drive revenue growth. The personalized medicine market is expected to reach $250 billion by 2029.

What Are BDX's Competitive Advantages?

• Established brand reputation and customer loyalty.
• Extensive product portfolio and diversified revenue streams.
• Global distribution network and market presence.
• Strong relationships with healthcare providers and institutions.
• Intellectual property protection through patents and trademarks.

What Does BDX Do?

Founded in 1897, Becton, Dickinson and Company (BDX) has evolved into a global medical technology leader. Initially focused on manufacturing thermometers and syringes, the company expanded its product line to include a comprehensive range of medical devices, laboratory equipment, and diagnostic products. Today, BDX operates through three primary segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment offers products such as peripheral IV catheters, needle-free IV connectors, and sharps disposal systems. The BD Life Sciences segment provides specimen and blood collection products, automated blood culturing systems, and diagnostic reagents. The BD Interventional segment focuses on hernia repair products, surgical instruments, and urology products. BDX serves a diverse customer base, including healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. With a strong global presence and a commitment to innovation, BDX is a key player in the medical technology industry, competing with companies like Edwards Lifesciences and Cardinal Health.

What Products and Services Does BDX Offer?

• Develops and manufactures medical supplies, including syringes, needles, and catheters.
• Produces laboratory equipment for clinical and research settings.
• Offers diagnostic products for disease detection and monitoring.
• Provides solutions for medication management and delivery.
• Manufactures products for specimen and blood collection.
• Develops surgical instruments and related products.
• Offers products for diabetes care, including pen needles and syringes.

How Does BDX Make Money?

• Develops, manufactures, and sells medical supplies, devices, and diagnostic products.
• Generates revenue through direct sales to healthcare institutions, physicians, and laboratories.
• Utilizes a global distribution network to reach customers worldwide.
• Invests in research and development to innovate and expand its product portfolio.

What Industry Does BDX Operate In?

Becton, Dickinson and Company operates in the medical instruments and supplies industry, which is characterized by continuous innovation, stringent regulatory requirements, and increasing demand for advanced healthcare solutions. The industry is driven by factors such as an aging population, rising prevalence of chronic diseases, and technological advancements. BDX competes with major players like Edwards Lifesciences Corporation and Cardinal Health, Inc. The company's diversified product portfolio and global presence provide a competitive edge in this dynamic market.

Who Are BDX's Key Customers?

• Healthcare institutions, including hospitals and clinics.
• Physicians and other healthcare professionals.
• Clinical laboratories and research institutions.
• Pharmaceutical companies.
• General public (for certain products like diabetes care).

Company Profile

Becton, Dickinson and Company operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Franklin Lakes, US. The company is led by CEO Thomas E. Polen Jr.. BDX has traded publicly since 1973.

Becton, Dickinson and Company Financial Trajectory

Becton, Dickinson and Company (BDX) reported $4.98B in revenue for Q2 2026, reflecting 5.7% growth compared to the prior quarter. The company recorded net income of $377.0M, with diluted EPS of $1.37. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, BDX averaged $0.83 in diluted EPS.

How Becton, Dickinson and Company Is Valued

Becton, Dickinson and Company carries a market capitalization of $51.7B, placing it in the large-cap category. Relative to its peer group, BDX's quantitative score of 72/100 is roughly in line with the peer average of 75/100.

Return on equity for Becton, Dickinson and Company stands at 4.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.2%, showing how much profit it generates from its asset base. BDX trades at a trailing price-to-earnings ratio of 36.45, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.94 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 2.7%, the inverse of the P/E and a quick read on earnings relative to price.

Becton, Dickinson and Company's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.18 places it in the grey zone, a middle ground that warrants monitoring.

Becton, Dickinson and Company has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 8.2% above estimates on average.

Wall Street analysts project Becton, Dickinson and Company revenue of about $19.22B for fiscal 2026, with EPS near $12.61. The estimate reflects 10 contributing analysts.

BDX Financials

BDX earnings history & estimates →

BDX Latest News

BDX Analyst Consensus

BDX MoonshotScore

Latest Becton, Dickinson and Company Analysis

BDX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources